The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising various combinations of (i) at least one of an interferon or an interferon inducer; (ii) at least one bronchodilator or a pharmaceutically acceptable salt thereof; (iii) at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof; and (iv) at least one of particles comprising at least one of metal having antiviral properties and particles comprising metal compounds having antiviral properties; to the airway of a subject in need of treatment for the pulmonary viral infection.

The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising various combinations of (i) at least one of an interferon or an interferon inducer; (ii) at least one bronchodilator or a pharmaceutically acceptable salt thereof; (iii) at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof; and (iv) at least one of particles comprising at least one of metal having antiviral properties and particles comprising metal compounds having antiviral properties; to the airway of a subject in need of treatment for the pulmonary viral infection.

Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

The present invention relates to an mTOR inhibitor containing adefovir or tenofovir or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

The present invention relates to a pharmaceutical composition, comprising at least one antiviral agent as an active agent, for use in the prevention or treatment of an infection by a neurotropic virus, in particular by a virus of the Coronaviridae family or by a virus of the Retroviridae family, wherein the pharmaceutical composition is administered by the nasal route, in particular through the olfactory nerve pathway.

The disclosure provides methods for treating vulvovaginal atrophy (VVA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

The disclosure provides methods for treating vulvovaginal atrophy (VVA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.